Esco Lifesciences Group Strengthens IVF Portfolio by Acquiring Evidence Solution

06 July 2022 | Wednesday | News

Esco Lifesciences Group ("Esco", the "Company") announces the full acquisition of Evidence Solution ("Evidence"), a Danish software company offering In Vitro Fertilization (IVF) management technologies and quality management systems ("Evidence witness system").
Image Source : Public Domain

Image Source : Public Domain

Evidence witness system is a witnessing, labelling, workflow scheduling and traceability system, specifically built for IVF clinics to prevent treatment errors.


"We are excited to welcome Evidence Solution to the Esco family. Evidence Solution is a young company established in 2019. With its innovative core technologies, the company has been expanding rapidly with a steadily growing client base," said XQ Lin, Chairman and CEO of Esco Lifesciences. "IVF market is expanding rapidly, through the inclusion of Evidence's witnessing feature to our best-in-class IVF devices, we will be able to provide our customers with more productive and compliant workflows." 

With over a decade's worth of dedication towards research and product development, Esco Medical (the IVF medical device arm of Esco) has become one of the global leaders in the IVF industry. The Company has been proactively expanding the range of its IVF solutions. In November 2021, Esco strategically invested in a Chinese medical company specialized in IVF-enabling tools and consumables, diving even deeper into the IVF segment. As Esco unveils its 3.0 transformation, going forward, the Company will continue to leverage its unique position as a Singapore-rooted life sciences company to bridge the east and the west for collaborations in life sciences.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in